A citation-based method for searching scientific literature

Ajay Varanasi, Natalie Bellini, Deepti Rawal, Mehul Vora, Antoine Makdissi, Sandeep Dhindsa, Ajay Chaudhuri, Paresh Dandona. Eur J Endocrinol 2011
Times Cited: 97



M Gutniak, C Orskov, J J Holst, B Ahrén, S Efendic. N Engl J Med 1992
Times Cited: 780




List of shared articles



Times cited

Non-insulin drugs to treat hyperglycaemia in type 1 diabetes mellitus.
Christian Seerup Frandsen, Thomas Fremming Dejgaard, Sten Madsbad. Lancet Diabetes Endocrinol 2016
45

Persistent C-peptide: what does it mean?
Massimo Pietropaolo. Curr Opin Endocrinol Diabetes Obes 2013
7

GLP-1 Receptor Agonists and Type 1 Diabetes - Where Do We Stand?
Djordje S Popovic, Edita Stokic, Stevan L Popovic. Curr Pharm Des 2015
4

Liraglutide for treating type 1 diabetes.
Thomas Fremming Dejgaard, Christian Seerup Frandsen, Jens Juul Holst, Sten Madsbad. Expert Opin Biol Ther 2016
8


Non-insulin pharmacological therapies for treating type 1 diabetes.
Christian Seerup Frandsen, Thomas Fremming Dejgaard, Sten Madsbad, Jens Juul Holst. Expert Opin Pharmacother 2018
4




Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes--a protocol for a randomised, double-blind, placebo-controlled study: the Lira-1 study.
Thomas Fremming Dejgaard, Filip Krag Knop, Lise Tarnow, Christian Seerup Frandsen, Tanja Stenbæk Hansen, Thomas Almdal, Jens Juul Holst, Sten Madsbad, Henrik Ullits Andersen. BMJ Open 2015
9

Twelve-Week Treatment With Liraglutide as Add-on to Insulin in Normal-Weight Patients With Poorly Controlled Type 1 Diabetes: A Randomized, Placebo-Controlled, Double-Blind Parallel Study.
Christian S Frandsen, Thomas F Dejgaard, Jens J Holst, Henrik U Andersen, Birger Thorsteinsson, Sten Madsbad. Diabetes Care 2015
50